论文部分内容阅读
目的评价FOLFOX4方案一线治疗晚期肝癌的近期疗效和不良反应。方法40例晚期肝癌,给予FOL-FOX4方案治疗。按RECIST标准评价近期疗效,WHO标准评价不良反应。结果40例患者获得CR4例,PR15例,SD5例,PD16例,DCR 60.0%。主要不良反应为恶心、呕吐、骨髓抑制及神经感觉异常。结论FOLFOX4方案治疗晚期肝癌有效,DCR较高,不良反应轻,患者可以耐受。
Objective To evaluate the short-term efficacy and side effects of first-line FOLFOX4 in the treatment of advanced liver cancer. Methods Forty patients with advanced hepatocellular carcinoma were treated with FOL-FOX4 regimen. According to RECIST standard evaluation of recent efficacy, WHO standard evaluation of adverse reactions. Results 40 patients were CR4 cases, PR15 cases, SD5 cases, PD16 cases, DCR 60.0%. The main adverse reactions were nausea, vomiting, myelosuppression and neurosensory abnormalities. Conclusion FOLFOX4 regimen is effective in treating advanced liver cancer with high DCR, mild adverse reactions and tolerable patients.